5 Best Pharma Dividend Stocks To Buy

In this article, we discuss 5 best pharma dividend stocks to buy. If you want to see more stocks in this selection, check out 10 Best Pharma Dividend Stocks To Buy. 

5. Zoetis Inc. (NYSE:ZTS)

Number of Hedge Fund Holders: 62

Dividend Yield as of October 27: 0.85%

Zoetis Inc. (NYSE:ZTS) is a New Jersey-based company that develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. On October 13, Zoetis Inc. (NYSE:ZTS) declared a $0.325 per share quarterly dividend, in line with previous. The dividend is payable on December 1, to shareholders of the company as of November 1. Zoetis Inc. (NYSE:ZTS) is one of the best dividend stocks to monitor. 

On October 17, JPMorgan analyst Chris Schott maintained an Overweight rating on Zoetis Inc. (NYSE:ZTS) but trimmed the price target on the shares to $225 from $250. The analyst noted that vet visit pressures remain but appear largely well reflected in the valuations of animal health names.

According to Insider Monkey’s data, 62 hedge funds were long Zoetis Inc. (NYSE:ZTS) at the end of Q2 2022, compared to 67 funds in the prior quarter. Peter Rathjens, Bruce Clarke, and John Campbell’s Arrowstreet Capital is the leading position holder in the company, with more than 2 billion shares worth $358.6 million. 

Here is what Baron Health Care Fund has to say about Zoetis Inc. (NYSE:ZTS) in its Q1 2022 investor letter:

“Shares of Zoetis Inc., the global leader in the discovery, development, and manufacturing of companion and farm animal health medicine and vaccines, fell along with shares of other high-multiple 2021 standout performers. We retain conviction as Zoetis recently reported a top and bottom line beat with more than 21% growth driven by dermatology, parasiticides, and recently launched monoclonal osteoarthritic treatments. The company’s 2022 guidance was in line with Street expectations, calling for 9% to 11% operational revenue growth and modest margin expansion despite heavy investment in core growth drivers.”